TEL AVIV – One injection of Covid-19, developed by Pfizer Inc. and BioNTech SE, 85% effective in preventing symptomatic diseases 15 to 28 days after application, an Israeli study has shown, a development that could help policy makers prioritize vaccines worldwide.
Some governments are debating whether to delay the second injection of the recommended two-dose regimen to take advantage of the vaccine shortage.
An Israeli study, conducted by the Sheba government medical center and released on Friday, also found a 75% reduction in all Covid-19 infections, symptomatic or asymptomatic, after the first shot. The peer-reviewed study was published in the British medical journal The Lancet as correspondence, meaning it represents the views of the authors, not the journal.
The data used were collected on 9,109 health workers of the center, who started the vaccination process starting on December 19th.
“This is the first study to evaluate the effectiveness of a single dose of the vaccine in real conditions and shows early efficacy, even before a second dose is given,” said Prof. Eyal Leshem, director of the Sheba Center for Travel Medicine and Tropical Diseases and one of the study’s authors.